Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/199885
Title: | Molecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis |
Author: | Pinyol, Roser Torrecilla, Sara Wang, Huan Montironi, Carla Piqué Gili, Marta Torres Martín, Miguel Wei-Qiang, Leow Willoughby, Catherine E. Ramadori, Pierluigi Andreu Oller, Carmen Taik, Patricia Lee, Youngmin A. Moeini, Agrin Peix, Judit Faure-Dupuy, Suzanne Riedl, Tobias Schuehle, Svenja Oliveira, Claudia P. Alves, Venancio A. Boffetta, Paolo Lachenmayer, Anja Roessler, Sthephanie Minguez, Beatriz Schirmacher, Peter Dufour, Jean-François Thung, Swan N. Reeves, Helen L. Carrilho, Flair J. Chang, Charissa Uzilov, Andrew V. Heikenwälder, Mathias Sanyal, Arun Friedman, Scott L. Sia, Daniela Llovet i Bayer, Josep Maria |
Keywords: | Models animals en la investigació Càncer de fetge Síndrome metabòlica Models moleculars Mutació (Biologia) Obesitat Animal models in research Liver cancer Metabolic syndrome Molecular models Mutation (Biology) Obesity |
Issue Date: | 13-May-2021 |
Publisher: | Elsevier |
Abstract: | Background and aims: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined. We aimed to identify unique molecular traits characterising NASH-HCC compared to other HCC aetiologies. Methods: We collected 80 NASH-HCC and 125 NASH samples from 5 institutions. Expression array (n = 53 NASH-HCC; n = 74 NASH) and whole exome sequencing (n = 52 NASH-HCC) data were compared to HCCs of other aetiologies (n = 184). Three NASH-HCC mouse models were analysed by RNA-seq/expression-array (n = 20). Activin A receptor type 2A (ACVR2A) was silenced in HCC cells and proliferation assessed by colorimetric and colony formation assays. Results: Mutational profiling of NASH-HCC tumours revealed TERT promoter (56%), CTNNB1 (28%), TP53 (18%) and ACVR2A (10%) as the most frequently mutated genes. ACVR2A mutation rates were higher in NASH-HCC than in other HCC aetiologies (10% vs. 3%, p <0.05). In vitro, ACVR2A silencing prompted a significant increase in cell proliferation in HCC cells. We identified a novel mutational signature (MutSig-NASH-HCC) significantly associated with NASH-HCC (16% vs. 2% in viral/alcohol-HCC, p = 0.03). Tumour mutational burden was higher in non-cirrhotic than in cirrhotic NASH-HCCs (1.45 vs. 0.94 mutations/megabase; p <0.0017). Compared to other aetiologies of HCC, NASH-HCCs were enriched in bile and fatty acid signalling, oxidative stress and inflammation, and presented a higher fraction of Wnt/TGF-β proliferation subclass tumours (42% vs. 26%, p = 0.01) and a lower prevalence of the CTNNB1 subclass. Compared to other aetiologies, NASH-HCC showed a significantly higher prevalence of an immunosuppressive cancer field. In 3 murine models of NASH-HCC, key features of human NASH-HCC were preserved. Conclusions: NASH-HCCs display unique molecular features including higher rates of ACVR2A mutations and the presence of a newly identified mutational signature. Lay summary: The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH) is increasing globally, but its molecular traits are not well characterised. In this study, we uncovered higher rates of ACVR2A mutations (10%) - a potential tumour suppressor - and the presence of a novel mutational signature that characterises NASH-related HCC. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2021.04.049 |
It is part of: | Journal of Hepatology, 2021, vol. 75, num. 4, p. 865-878 |
URI: | https://hdl.handle.net/2445/199885 |
Related resource: | https://doi.org/10.1016/j.jhep.2021.04.049 |
ISSN: | 0168-8278 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
718036.pdf | 664.46 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License